Back to top
more

CytomX Therapeutics (CTMX)

(Delayed Data from NSDQ)

$1.01 USD

1.01
1,066,225

-0.04 (-3.81%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $0.99 -0.02 (-1.98%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy

by Zacks Equity Research

The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.

Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects

by Zacks Equity Research

Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.

Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study

by Zacks Equity Research

After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.

Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study

by Zacks Equity Research

Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.

Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data

by Zacks Equity Research

Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

by Zacks Equity Research

Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

by Zacks Equity Research

The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.

J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag

by Zacks Equity Research

FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.

Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.

Apellis (APLS) Rides on Syfovre to Fuel Growth Amid Rivalry

by Zacks Equity Research

Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe.

AstraZeneca (AZN) to Discontinue Two Studies on Lokelma

by Zacks Equity Research

Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.

Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why

by Zacks Equity Research

Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.

AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study

by Zacks Equity Research

Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.

FDA Accepts Karuna's (KRTX) NDA Filing for Schizophrenia Drug

by Zacks Equity Research

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. A final decision is expected in September 2024.

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

by Zacks Equity Research

Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.

Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine

by Zacks Equity Research

The BARDA is exercising an option to procure additional doses of Emergent BioSolutions' (EBS) recently approved anthrax vaccine. Deliveries will likely be completed by the end of first-quarter 2024.

Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data

by Zacks Equity Research

Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.

SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug

by Zacks Equity Research

The FDA approves SpringWorks' (SWTX) Ogsiveo (nirogacestat) for the treatment of adult patients with desmoid tumors. Shares rise.

Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study

by Zacks Equity Research

Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.

TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug

by Zacks Equity Research

The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.

GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study

by Zacks Equity Research

GSK announces positive data from the DREAMM-7 head-to-head phase III study evaluating Blenrep for second-line treatment of relapsed or refractory multiple myeloma. The study meets its primary endpoint.

CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why

by Zacks Equity Research

CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the United Kingdom.

Vertex (VRTX) Gets EU Nod for Kaftrio Use in 2-5 Year Kids

by Zacks Equity Research

The European Commission approves Vertex's (VRTX) Kaftrio for expanded use to treat children aged two to five years with cystic fibrosis.

Freeline (FRLN) Shares Rise on Merger Agreement With Syncona

by Zacks Equity Research

Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down

by Zacks Equity Research

The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.